Global Acetazolamide Market Size, Share and Trends Analysis Report, By Type (Tablet, Capsule, and Injection), By Application (Glaucoma, Epilepsy, Drug-induced Edema, Altitude Sickness, Fluid Retention, Heart Failure, and Seizures), and By Distribution Channels (Hospital, Drug Store, and Online Pharmacies), Forecast (2022-2028)

The global acetazolamide market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Acetazolamide is a carbonic anhydrase inhibitor used to treat chronic simple (open-angle) glaucoma, secondary glaucoma, acute angle-closure glaucoma, epilepsy, edoema from congestive heart failure, drug-induced edoema, and acute mountain sickness in climbers. Acetazolamide aids altitude adaptation by increasing renal bicarbonate production, inducing metabolic acidosis, and stimulating breathing. Thus, the rising demand and requirement for acetazolamide drug to treat such health concerns is expected to bolster the market’s growth globally.

Increasing prevalence of glaucoma and associated risk factors such as high myopia, diabetes, eye surgery or injury, high blood pressure, and increased use of corticosteroids are expected to provide favorable growth opportunities for the acetazolamide drug manufacturers. According to the Centers for Disease Control and Prevention (CDC), in November 2022, around 3 million people in the US were diagnosed with glaucoma. Glaucoma is also considered to be the cause of blindness. Acetazolamide drugs lowers ocular pressure prevents damage to the eyes. In addition, it also reduces ocular pressure by inhibiting the function of an enzyme known as carbonic anhydrase, which deacreases the quantity of fluid secreted in the the eye.

Growing healthcare infrastructures across various emerging nations such as China, India and others along with high prevalence of glaucoma is another factor propelling the growth of the market in Asia-Pacific region. According to the studies revealed by the National Health Portal, in March 2019, glaucoma is the major cause of permanent blindness in India, which affects approximately 12 million people and leaving around 1.2 million blind each  year. Additionally, more than 90% of instances of glaucoma go misdiagnosed. Glaucoma is more common as people get older, thus the rising geriatric population across the Asia-Pacific region is anticipated to drive the growth of the market.

Another major factor contributing towards the rising incidence of glaucoma across the globe is the long working hours. As a result of which, there is rapid surge in demand for drive-through locations which in turn drives the expansion of the pharmacies and drugstores sector.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
  • By Distribution Channels
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-Teva Pharmaceutical Industries Ltd., Accord Healthcare, Avet Pharmaceuticals Inc., Nostrum Laboratories Inc., Zydus Pharmaceuticals, Inc. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Acetazolamide  Market Report by Segment

By Type

• Tablet
• Capsule
• Injection

By Application

• Glaucoma
• Epilepsy
• Drug-induced Edema
• Altitude Sickness
• Fluid Retention
• Heart Failure
• Seizures

By Distribution Channels

• Hospital
• Drug Store
• Online Pharmacies

Global Acetazolamide  Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa